Key facts
- This page summarizes Enavate Sciences GP, LLC's Form 4 filing for Zenas BioPharma, Inc. (ZBIO).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Sep 2024, 16:15.
Enavate Sciences GP, LLC - 16 Sep 2024 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ZBIO
- Reported as of
- 16 Sep 2024
- Net transaction value
- +$15,000,001
- SEC form
- 4
- Accepted by SEC
- 18 Sep 2024, 16:15:14 UTC
- Prior SEC filing
- 12 Sep 2024
- Next SEC filing
- 10 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- Enavate Sciences GP, LLC, By: /s/ James P. Boylan, Manager
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Enavate Sciences GP, LLC filed Form 4 for Zenas BioPharma, Inc. (ZBIO) on 18 Sep 2024.
Change
- Previous filing in this sequence was filed on 12 Sep 2024.
- Current net transaction value: +$15,000,001.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZBIO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,879,006
- Change %
- Price
- Shares after
- 2,879,006
- Date
- 16 Sep 2024
- Ownership
- By Zebra Aggregator, LP
- Footnotes
- F1, F2
ZBIO
transaction
Common Stock
Purchase
- Transaction value
- $15,000,001
- Shares
- +882,353
- Change %
- +31%
- Price
- $17.00
- Shares after
- 3,761,359
- Date
- 16 Sep 2024
- Ownership
- By Zebra Aggregator, LP
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZBIO
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -10,474,889
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- By Zebra Aggregator, LP
- Underlying class
- Common Stock
- Underlying amount
- 1,206,353
- Exercise price
- Footnotes
- F1, F2
ZBIO
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -14,523,821
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- By Zebra Aggregator, LP
- Underlying class
- Common Stock
- Underlying amount
- 1,672,653
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Enavate Sciences GP, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on an 8.6831-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock has no expiration date.
Footnote F2
Shares are directly held by Zebra Aggregator, LP ("Zebra"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Zebra and may be deemed to share voting and investment power with respect to the shares held by Zebra. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.